HuGE Literature Finder
Records 1-5
|
No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study.
Cancers 2021 Jan 13 (3): . Guida Michele, Bartolomeo Nicola, Quaglino Pietro, Madonna Gabriele, Pigozzo Jacopo, Di Giacomo Anna M, Minisini Alessandro M, Tucci Marco, Spagnolo Francesco, Occelli Marcella, Ridolfi Laura, Queirolo Paola, De Risi Ivana, Quaresmini Davide, Gambale Elisabetta, Chiaron Sileni Vanna, Ascierto Paolo A, Stigliano Lucia, Strippoli Sabino, On Behalf Of The Italian Melanoma Intergroup Imi Stud |
|
Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients.
Scientific reports 2020 Oct 10 (1): 17687. Aoude Lauren G, Bonazzi Vanessa F, Brosda Sandra, Patel Kalpana, Koufariotis Lambros T, Oey Harald, Nones Katia, Wood Scott, Pearson John V, Lonie James M, Arneil Melissa, Atkinson Victoria, Smithers B Mark, Waddell Nicola, Barbour Andrew |
|
CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients.
Journal of the American Academy of Dermatology 2018 Sep . Dalmasso Bruna, Pastorino Lorenza, Ciccarese Giulia, Andreotti Virginia, Grillo Federica, Mastracci Luca, Spagnolo Francesco, Ballestrero Alberto, Queirolo Paola, Bruno William, Ghiorzo Pao |
|
Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases.
Journal of the National Cancer Institute 2016 Nov 108 (11): . Helgadottir Hildur, Höiom Veronica, Tuominen Rainer, Nielsen Kari, Jönsson Göran, Olsson Håkan, Hansson Joh |
|
BRAF mutations in advanced cancers: clinical characteristics and outcomes.
PloS one 2011 6 (10): e25806. El-Osta Hazem, Falchook Gerald, Tsimberidou Apostolia, Hong David, Naing Aung, Kim Kevin, Wen Sijin, Janku Filip, Kurzrock Razel |
- Page last reviewed:Oct 1, 2020
- Page last updated:Feb 24, 2021
- Content source: